Model Complexes for the Nip Site of Acetyl Coenzyme A Synthase/Carbon Monoxide (CO) Dehydrogenase: Structure, Electrochemistry, and CO Reactivity.

Aliphatic thiolato-S-bridged tri- and binuclear nickel(II) complexes have been synthesized and characterized as models for the Nip site of the A cluster of acetyl coenzyme A synthase (ACS)/carbon monooxide (CO) dehydrogenase. Reaction of the in situ formed N2Sthiol donor ligands with [Ni(H2O)6](ClO4)2 afforded the trinuclear complexes [Ni{(LMe(S))2Ni}2](ClO4)2·CH3CN (1·CH3CN) and [Ni{(LBr(S))2Ni}2](ClO4)2·5H2O (2·5H2O) following self-assembly. Complexes 1 and 2 react with [Ni(dppe)Cl2] and dppe [dppe = 1,2-bis(diphenylphosphino)ethane] to afford the binuclear [Ni(dppe)Ni(LMe(S))2](ClO4)2·2H2O (3·2H2O) and [Ni(dppe)Ni(LBr(S))2](ClO4)2·0.75O(C2H5)2 [4·0.75O(C2H5)2], respectively. The X-ray crystal structures of 1-4 revealed a central NiIIS4 moiety in 1 and 2 and a NiIIP2S2 moiety in 3 and 4; both moieties have a square-planar environment around Ni and may mimic the properties of the Nip site of ACS. The electrochemical reduction of both terminal NiII ions of 1 and 2 occurs simultaneously, which is further confirmed by the isolation of [Ni{(LMe(S))2Ni(NO)}2](ClO4)2 (5) and [Ni{(LBr(S))2Ni(NO)}2](ClO4)2 (6) following reductive nitrosylation of 1 and 2. Complexes 5 and 6 exhibit νNO at 1773 and 1789 cm-1, respectively. In the presence of O2, both 5 and 6 transform to nitrite-bound monomers [(LMe(S-S))Ni(NO2)](ClO4) (7) and [(LBr(S-S))Ni(NO2)](ClO4)2 (8). The nature of the ligand modification is evident from the X-ray crystal structure of 7. To understand the origin of multiple reductive responses of 1-4, complex [(LMe(SMe))2Ni](ClO4)2 (9) is considered. The central NiS4 part of 1 is labile like the Nip site of ACS and can be replaced by phenanthroline. The treatment of CO to reduce 3 generates a 3red-(CO)2 species, as confirmed by Fourier transform infrared (νCO = 1997 and 2068 cm-1) and electron paramagnetic resonance ( g1 = 2.18, g2 = 2.13, g3 = 1.95, and AP = 30-80 G) spectroscopy. The CO binding to NiI of 3red is relevant to the ACS activity.

A Copper(II) Nitrite That Exhibits Change of Nitrite Binding Mode and Formation of Copper(II) Nitrosyl Prior to Nitric Oxide Evolution.

The proton-coupled reduction of CuII-bound nitrite (NO2-) to nitric oxide (NO2- + 2H+ + e- → NO(g) + H2O), such as occurs in the enzyme copper nitrite reductase, is investigated in this work. Our studies focus on the copper(II/I) model complexes [(L2)Cu(H2O)Cl] (1), [(L2)Cu(ONO)] (2), [(L2)Cu(CH3CO2)] (3), and [Co(Cp)2][(L2)Cu(NO2)(CH3CN] (4), where HL2 = N-[2-(methylthio)ethyl]-2'-pyridinecarboxamide. Complex 1 readily reacts with a NO2- anion to form the nitrito-O-bound copper(II) complex 2. Electrochemical reduction of CuII → CuI indicates coordination isomerization from asymmetric nitrito-κ2-O,O to nitro-κ1-N. Isolation and spectroscopic characterization of 4 support this notion of nitrite coordination isomerization (νCu-N ∼ 460 cm-1). A reduction of 2, followed by reaction with acetic acid, causes evolution of stoichiometric NO via the transient copper(II) nitrosyl species and subsequent formation of the acetate-bound complex 3. The probable copper nitrosyl intermediate [(L2)Cu(NO)(CH3CN)]+ of the {CuNO}10 type is evident from low-temperature UV-vis absorption (λmax = 722 nm) and electron paramagnetic resonance spectroscopy. A density functional theory (DFT)-optimized model of [(L2)Cu(NO)(CH3CN)]+ shows end-on NO binding to Cu with Cu-N(NO) and N-O distances of 1.989 and 1.140 Å, respectively, and a Cu-N-O angle of 119.25°, consistent with the formulation of CuII-NO•. A spin-state change that triggers NO release is observed. Considering singlet- and triplet-state electronic configurations of this model, DFT-calculated νNO values of 1802 and 1904 cm-1, respectively, are obtained. We present here important mechanistic aspects of the copper-mediated nitrite reduction pathway with the use of model complexes employing the ligand HL2 and an analogous phenyl-based ligand, N-[2-(methylthio)phenyl]-2'-pyridinecarboxamide (HL1).